| Dr Maura L Sparks, MD | |
|
372 Danbury Rd, Suite 180, Wilton, CT 06897-2523 | |
| (203) 276-4015 | |
| (203) 834-2639 |
| Full Name | Dr Maura L Sparks |
|---|---|
| Gender | Female |
| Speciality | Internal Medicine |
| Experience | 23 Years |
| Location | 372 Danbury Rd, Wilton, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1124020516 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 045756 (Connecticut) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Stamford Hospital | Stamford, CT | Hospital |
| Norwalk Hospital | Norwalk, CT | Hospital |
| Danbury Hospital | Danbury, CT | Hospital |
| Yale-new Haven Hospital | New haven, CT | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Stamford Health Medical Group Inc | 6901099746 | 355 |
| Rehabilitation Associates Inc | 8022905322 | 297 |
News Archive
There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers.Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute may have solved the problem by developing a new mathematical model that encompasses all dose levels.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
Cellular Dynamics International, the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells under a feeder-free condition using chemically defined media.
Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.
Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.
› Verified 4 days ago
| Entity Name | Stamford Health Medical Group Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154633980 PECOS PAC ID: 6901099746 Enrollment ID: O20101025000743 |
News Archive
There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers.Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute may have solved the problem by developing a new mathematical model that encompasses all dose levels.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
Cellular Dynamics International, the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells under a feeder-free condition using chemically defined media.
Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.
Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Maura L Sparks, MD 372 Danbury Rd, Suite 180, Wilton, CT 06897-2523 Ph: (203) 276-4015 | Dr Maura L Sparks, MD 372 Danbury Rd, Suite 180, Wilton, CT 06897-2523 Ph: (203) 276-4015 |
News Archive
There is yet no straightforward way to determine the optimal dose level and treatment schedules for high-dose radiation therapies such as stereotactic radiation therapy, used to treat brain and lung cancer, or for high-dose brachytherapy for prostate and other cancers.Radiation oncologists at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute may have solved the problem by developing a new mathematical model that encompasses all dose levels.
e-Therapeutics plc announces that it has started a randomised double-blind controlled phase IIb trial of ETS6103 in major depressive disorder.
Cellular Dynamics International, the world's largest producer of human tissue cells for drug discovery and safety testing, today announced the publication of research demonstrating an efficient and scalable method of creating DNA integration-free, or footprint-free, induced pluripotent stem cells under a feeder-free condition using chemically defined media.
Research presented today showed that the investigational drug, LAF237, the first in a new class, improved glycemic control in patients with type 2 diabetes. In this study, LAF237, which is administered as a tablet to be taken orally, was added to the standard diabetes treatment metformin in patients whose diabetes was not adequately controlled by metformin alone.
Teva Pharmaceutical Industries Ltd. announced today the acquisition of Corporación Infarmasa, a top ten pharmaceutical company in Perú, from The Rohatyn Group and Altra Investments.
› Verified 4 days ago
Pamela Joy Randolph, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 249 Danbury Road, Wilton, CT 06897 Phone: 203-852-2270 Fax: 203-899-5027 | |
Dr. Craig David Serin, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Danbury Rd, Davenport Building, Suite 140, Wilton, CT 06897 Phone: 203-762-3353 Fax: 203-761-8563 | |
Dr. Sarah Kahn, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 195 Danbury Rd, Wilton, CT 06897 Phone: 203-276-8490 Fax: 203-276-8491 | |
Varshapriya Iyer, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 436 Danbury Rd, Wilton, CT 06897 Phone: 203-210-7575 Fax: 203-210-7573 | |
Dr. Ahsan Fayyaz Malik, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 20 Old Ridgefield Rd, Wilton, CT 06897 Phone: 203-762-5588 Fax: 203-762-2301 | |
Dr. Karen R Silverberg, M.D. Internal Medicine Medicare: Not Enrolled in Medicare Practice Location: 150 Pipers Hill Rd, Wilton, CT 06897 Phone: 203-762-3507 |